Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Original Article

L.S. Honig, B. Vellas, M. Woodward, M. Boada, R. Bullock, M. Borrie, K. Hager, N. Andreasen, E. Scarpini, H. Liu-Seifert, M. Case, R.A. Dean, A. Hake, K. Sundell, V.P. Hoffmann, C. Carlson, R. Khanna, M. Mintun, R. DeMattos, K.J. Selzler, and E. Siemers

N Engl J Med 2018;378:321-330

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
01/24/2018
Course expires: 
01/25/2020

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please sign in or create an account to take the course.